清纤方治疗慢性乙肝肝纤维化临床观察  

Effect of Qingxianfang in Treating Chronic Hepatitis B with Liver Fibrosis

作　　者：张林军[1] 刘静[2] 张明辉[2] 常风云[3] 董尚朴[4] 刘军[1] 马洪波[1] 白朝辉[1] 

机构地区：[1]河北体育学院医院,河北石家庄050061 [2]河北医科大学第一医院,河北石家庄050031 [3]河北医科大学中西医结合学院,河北石家庄050091 [4]河北医科大学中医学院,河北石家庄050091

出　　处：《辽宁中医杂志》2008年第11期1681-1682,共2页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的:探讨清纤方对慢性乙肝肝纤维化的治疗机制。方法:165例患者随机分治疗组105例和对照组60例,分别采用清纤方和IFNα-2b治疗。观察症状、肝功能、肝纤四项和HBeAg、HBV-DNA的变化。结果:治疗组症状、肝功能、肝纤四项明显优于照组(P<0.05,P<0.01),HBeAg、HBV-DNA与对照组比较无明显差异(P>0.05)。结论:清纤方治疗慢性乙肝肝纤维化有较好疗效。Objective： To explore the therapy of Qingxianfang in treating chronic hepatitis B with liver fibrosis. Method： 165patients were random divided into treatment group 105 examples and control group 60 examples, were treated respectively by Qingxianfang and IFN α -2b. Observe the change of symptom integral,liver function, 4 - items liver fibrosis and HBeAg,HBV-DNA. Result ： The treatment group＇ s symptom integral,liver function, 4 - items liver fibrosis are superior to the control group （P 〈0.05, P 〈0.01）, HBeAg, HBV -DNA have no too much difference（ P 〉0.05 ）. Conclusion：Qingxianfang has better effect in treating chronic hepatitis B with liver fibrosis.

关 键 词：慢性乙肝 肝纤维化 复合物 清纤方 IFNΑ-2B 

分 类 号：R256.42[医药卫生—中医内科学]